Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w/Chronic HBV Infection.

Summary

Provide adefovir dipivoxil (Hepsera) 10 mg once daily to patients with chronic hepatitis B virus (HBV) infection who have completed a Gilead-sponsored study of adefovir dipivoxil and require continued access to adefovir dipivoxil.

Timeline

Start

2002-01

Primary completion

—

Completion

2005-01

Outcome

Outcome not reported

Stopped: “The study stopped due to marketing approval by the FDA.”

Drugs

Indications